Among the 21 Wall Street analysts covering Cardinal Health, Inc. (CAH), the highest published price target sits at $275 — a level maintained most prominently by TD Cowen and Leerink Partners. With the stock trading near $236 and the consensus analyst target averaging approximately $252 to $255, the $275 mark represents the outer boundary of mainstream bullish expectations. Reaching it would require the stock to surpass its current 52-week high of roughly $245 and push through the psychologically significant $250 threshold, neither of which has occurred in the company's trading history.
Cardinal Health, headquartered in Dublin, Ohio, is one of the "Big Three" pharmaceutical distributors in the United States alongside McKesson Corporation (MCK) and Cencora, Inc. (COR). Together, these three firms control over 90% of the U.S. pharmaceutical wholesale market. Cardinal Health operates through two primary segments: Pharmaceutical and Specialty Solutions, which accounts for roughly 92% of segment revenue and involves distributing branded, generic, and specialty drugs to pharmacies and healthcare providers; and Global Medical Products and Distribution, which manufactures and sells medical-surgical supplies. The company also operates a growing portfolio of specialty healthcare services, including nuclear pharmacies and logistics solutions.
Cardinal Health's stock has delivered a remarkable run, gaining approximately 56% over the past 12 months and more than 400% over the past five years. The company generated roughly $250 billion in trailing twelve-month revenue, supported by a market capitalization near $55 billion. In its most recent fiscal quarter, the company posted an 11% year-over-year revenue increase while adjusted earnings per share (EPS) jumped nearly 35%, comfortably exceeding Wall Street estimates. Management raised full-year fiscal 2026 adjusted EPS guidance to a range of $10.70 to $10.80, reflecting confidence in sustained momentum across the specialty drug portfolio.
Several structural tailwinds support the case for Cardinal Health reaching $275. The company's specialty pharmaceuticals business — encompassing oncology therapies, GLP-1 weight-loss medications, biosimilars, and other high-cost drugs — has been growing at a double-digit compound annual rate. Specialty revenues are projected to exceed $50 billion, representing a roughly 16% three-year compound annual growth rate (CAGR). An aging U.S. population provides a durable demographic tailwind for pharmaceutical demand. Additionally, Cardinal Health has deployed significant capital toward strategic acquisitions, including a $1.9 billion purchase of Solaris Health to expand urology services, a $1 billion acquisition of Advanced Diabetes Supply Group for home healthcare, and a $2.8 billion majority stake in GI Alliance for gastroenterology management. These acquisitions diversify revenue streams into higher-margin specialty care services.
The analyst community maintains a broadly constructive stance on Cardinal Health. Of the 21 analysts providing ratings, the overwhelming majority hold Buy or equivalent ratings, with the consensus landing firmly in "Strong Buy" territory. The average analyst price target stands at approximately $252 to $255, while the median target sits near $260. Recent target increases have been frequent: Citigroup raised its target from $245 to $265 in late July 2026, UBS boosted its target from $260 to $274, and TD Cowen lifted its target from $255 to $275. Only JPMorgan maintains a notably cautious Neutral rating with a $215 target. The trend of upward revisions suggests growing confidence in the company's earnings trajectory, though the $275 level remains an ambitious outlier relative to the consensus.
Several risks could keep Cardinal Health from reaching $275. The pharmaceutical distribution industry operates on exceptionally thin gross margins — typically around 3% to 4% — leaving little room for operational error. Pricing scrutiny from regulators and reimbursement pressure on pharmacy and provider customers represent ongoing headwinds. The company also faces customer concentration risk; the loss of a major pharmacy chain contract could materially impact revenue. Furthermore, Cardinal Health's trailing price-to-earnings (P/E) ratio of approximately 36 sits well above the healthcare industry average near 25, raising questions about whether the current valuation already prices in optimistic growth assumptions. Integration risks associated with multiple large-scale acquisitions also warrant caution.
From a technical analysis perspective, the immediate hurdle for Cardinal Health is the 52-week high near $245, which has served as a resistance level in recent trading sessions. Beyond that, the $250 mark represents a psychological round-number resistance that the stock has never traded above. A sustained breakout above $250 would likely generate significant momentum and potentially attract additional institutional buying. On the downside, the $215 to $220 zone — which corresponds with the lowest analyst target and previous consolidation areas — represents a key support level that would need to hold for the bullish thesis to remain intact. The stock's low beta of approximately 0.4 to 0.5 indicates relatively low volatility compared to the broader market, suggesting that any move toward $275 would likely unfold gradually rather than through sharp spikes.
Navigating a stock like Cardinal Health requires staying ahead of shifting market conditions, which is where tools like Tickeron's AI Daily Buy/Sell Signals can assist. This platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving technical patterns, market behavior, and AI-driven analysis. Traders can leverage these signals to identify emerging opportunities, monitor existing positions more efficiently, and detect changes in market trends before they become obvious. Whether CAH approaches the $275 target or encounters resistance along the way, AI-powered signals may help investors stay informed and responsive to real-time developments.
The $275 price target for Cardinal Health represents an ambitious but not unreasonable objective. The strongest arguments in its favor include accelerating specialty drug revenue, a growing portfolio of higher-margin healthcare services from strategic acquisitions, consistent earnings beats, and strong demographic tailwinds. However, the stock already trades at a premium valuation relative to industry peers, and thin margins in the core distribution business leave limited tolerance for missteps. Reaching $275 would likely require flawless execution on acquisition integration, continued double-digit growth in specialty pharmaceuticals, and a market environment that continues rewarding healthcare stocks with premium multiples. Investors should monitor quarterly earnings reports for sustained EPS momentum, any signs of margin compression, and whether the stock can decisively break above the $245-to-$250 resistance zone in the months ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsA.I.dvisor indicates that over the last year, CAH has been loosely correlated with MCK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if CAH jumps, then MCK could also see price increases.
| Ticker / NAME | Correlation To CAH | 1D Price Change % | ||
|---|---|---|---|---|
| CAH | 100% | -0.53% | ||
| MCK - CAH | 66% Loosely correlated | -0.21% | ||
| COR - CAH | 57% Loosely correlated | -1.40% | ||
| HSIC - CAH | 23% Poorly correlated | -0.11% | ||
| YI - CAH | 5% Poorly correlated | +6.47% | ||
| COSM - CAH | 0% Poorly correlated | +5.43% | ||
More | ||||